1. 14 days after randomization 2. Hospital discharge (including transfer to an alternate care facility) 3. Death 4. CK noted to exceed 5,000 U/L (in the absence of an alternative diagnosis) or patient is determined to have clinical myositis or myopathy (at the discretion of the primary care team, patient may be re-challenged with study drug if CK or clinical findings no longer meet this criterion). 5. Alanine aminotransferase (ALT) exceeds 8 times the ULN (in the absence of an alternative diagnosis) 6. Co-administration of any of the following: niacin, fenofibrate, cyclosporine, gemfibrozil, lopinavir, ritonavir, oral contraceptives or estrogen 7. Attending physician or intensivist or SDM request to stop treatment.